首页> 外文OA文献 >Survival-adjusted health-related quality of life (HRQL) among patients with metastatic breast cancer receiving paclitaxel plus bevacizumab versus paclitaxel alone: results from Eastern Cooperative Oncology Group Study 2100 (E2100)

【2h】

Survival-adjusted health-related quality of life (HRQL) among patients with metastatic breast cancer receiving paclitaxel plus bevacizumab versus paclitaxel alone: results from Eastern Cooperative Oncology Group Study 2100 (E2100)

机译：在接受紫杉醇加上贝伐单抗的转移乳腺癌患者与单独的紫杉醇和紫杉醇的患者中存在的生存健康的生命质量（HRQL）：东方合作肿瘤学研究2100（E2100）的结果

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
David Cella; Molin Wang; Lynne Wagner; Kathy Miller;
展开▼
作者单位

展开▼
年度 2011
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Survival-adjusted health-related quality of life (HRQL) among patients with metastatic breast cancer receiving paclitaxel plus bevacizumab versus paclitaxel alone: Results from Eastern Cooperative Oncology Group Study 2100 (E2100) [J] . CellaD., WangM., WagnerL., Breast cancer research and treatment. . 2011,第3期

机译：接受紫杉醇联合贝伐单抗和单独紫杉醇治疗的转移性乳腺癌患者的生存调整后健康相关生活质量（HRQL）：来自东部合作肿瘤小组研究2100（E2100）的结果
2. Survival-adjusted health-related quality of life (HRQL) among patients with metastatic breast cancer receiving paclitaxel plus bevacizumab versus paclitaxel alone: results from Eastern Cooperative Oncology Group Study 2100 (E2100) [J] . David Cella, Molin Wang, Lynne Wagner, Breast Cancer Research and Treatment . 2011,第3期

机译：接受紫杉醇联合贝伐单抗和单独紫杉醇治疗的转移性乳腺癌患者的生存调整后健康相关生活质量（HRQL）：来自东部合作肿瘤小组研究2100（E2100）的结果
3. 275 ORAL First-line bevacizumab and paclitaxel in patients with locally recurrent or metastatic breast cancer: a randomized, phase III trial coordinated by the Eastern Cooperative Oncology Group (E2100) [J] . European Journal of Cancer Supplements . 2005,第2期

机译：275口服贝伐单抗和紫杉醇一线治疗局部复发或转移性乳腺癌的患者：由东部合作肿瘤小组（E2100）协调的一项随机III期试验
4. Correlations between depressive symptoms and quality of life in metastatic breast cancer patients during chemotherapy [C] . Dragomir B.I., Campean A. European Association of Psychosomatic Medicine., Annual Meeting. . 2014

机译：化疗期间转移性乳腺癌患者抑郁症状与生活质量的相关性
5. Cost-Benefit Analysis of Nanoparticle Albumin-Bound Paclitaxel versus Solvent-Based Paclitaxel for the Treatment of Metastatic Breast Cancer in the United States [D] . Vichansavakul, Kittaya 2013

机译：纳米白蛋白结合紫杉醇与溶剂型紫杉醇在美国治疗转移性乳腺癌的成本效益分析
6. Survival-adjusted health-related quality of life (HRQL) among patients with metastatic breast cancer receiving paclitaxel plus bevacizumab versus paclitaxel alone: results from Eastern Cooperative Oncology Group Study 2100 (E2100) [O] . David Cella, Molin Wang, Lynne Wagner, -1

机译：在接受紫杉醇加上贝伐单抗的转移乳腺癌患者与单独的紫杉醇和紫杉醇的患者中存在的生存健康的生命质量（HRQL）：东方合作肿瘤学研究2100（E2100）的结果
7. Independent Review of E2100: A Phase III Trial of Bevacizumab Plus Paclitaxel Versus Paclitaxel in Women With Metastatic Breast Cancer [O] . Gray, Robert, Bhattacharya, Suman, Bowden, Christopher, 2009

机译：E2100的独立审查：贝伐单抗加紫杉醇与紫杉醇对转移性乳腺癌妇女的III期试验

Survival-adjusted health-related quality of life (HRQL) among patients with metastatic breast cancer receiving paclitaxel plus bevacizumab versus paclitaxel alone: results from Eastern Cooperative Oncology Group Study 2100 (E2100)

著录项

相似文献

相关主题

期刊订阅